out LCC AMR UAUA>> oil gonna drop

2-6 scan: PIR>> who'd a thunk it lol

just loaded more 6.33 this is nutzzzzzzzz lol

added MF 6.50

added on dip>> UPDV

URRE sweet

ZILLA!!! ;o)

GM - thought ESLR would drop on AH news yest but turned out it was good for a quickie lol; saw u played it too ;o)

RSMI/RSMIE>>happy w/my trades; wouldn't hold this (or any other) POS o/n for ANY reason, but GLTY :)

NITE mutt has been playing games>>RSMI

RSMI>> major POS going pink & gonna sink into oblivion; u must be one of the few left in; all out now in between the spread .0017 & .0018 from .0009

GLTY

NITE playing games on the ASK here>>RSMI


"So we sailed up to the sun...till we found a sea of green..."

dunno; maybe the "spam-a-lot gang" hasn't spread the word...lol

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=30227522

APDR super-sub now; new 52-wk low .0008

APDR POS is a super-sub now; new 52-wk low .0008

need a crystal ball for crude then can play these like clockwork some decent bounces when oil drops

JBLU new lows; all airline charts lookin bout the same; toss a dart or stay away for now?

As of today (Friday, 20 June 2008), it's still DIOMQ.PK on Yahoo & Pinksheets.com.

I sold almost all on that Monday pop to .05 (back in March, I think), & then dumped all the rest of my freebies out mostly on the bid about a month later (it took a while and wasn't an easy thing to do when there was almost no buying for a while back then).

It's all dead money now, IMO, but nevertheless I wish any still in this Good Luck & that any shareholders remaining get something out of this mess.

GLTY

Grants Exceeding $5 Million Could Help Synthetic Blood International Become A Multi-Product CompanyLast update: 6/20/2008 8:55:01 AM

COSTA MESA, Calif., Jun 20, 2008 (BUSINESS WIRE) -- Synthetic Blood International, Inc. (SYBD) today announced that grants awarded by the Department of Defense to study clinical applications for Oxycyte(R) total more than $5.3 million. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier. The grants, which have been previously announced, are summarized below:

-- Virginia Commonwealth University Reanimation Engineering Shock Center (VCURES) received $1.3 million under a previously awarded U.S. Office of Naval Research grant for the treatment and prevention of decompression sickness (DCS) with Oxycyte.

-- A $1.6 million grant (over 3 years) was made for support of research into Oxycyte's ability to treat/prevent organ damage from arterial gas embolism (AGE). AGE is a potential result of DCS but also occurs during a number of surgical procedures including cardiac surgery, orthopedic-joint replacement, gynecologic surgery, and neurosurgery.

-- Approximately $1.2 million (over 3 years) will be utilized in ongoing studies of perfluorocarbon emulsions in the treatment of severe DCS, which occurs in dive accidents, mine workers, high altitude and space flight, and is a potential complication of rescue from a disabled submarine.

-- A $300,000 dollar grant (over two years) was made to sponsor a post-doctoral candidate to work in the microcirculation laboratories of VCURES supporting research in AGE, DCS, as well as other work in traumatic brain injury (TBI).

-- $300,000 was awarded to develop pilot studies into the effectiveness of Oxycyte in treating TBI secondary to a blast. Blast injury is the largest single cause of mortality and long term morbidity for coalition troops stationed in Iraq and Afghanistan. The VCURES work in blast injury will carefully dovetail with other Oxycyte research in TBI.

-- $600,000 from the United States Army is a sub-award from the $1.9 million grant to M. Ross Bullock, M.D., Ph.D., of the University of Miami Miller School of Medicine, Department of Neurosurgery. This money will support the VCURES efforts in the human civilian brain injury trial.

"The $5.3 million total represents only grants specifically dedicated to Oxycyte. It does not include grant funds in which Oxycyte was one among other drug studies," said company chairman and CEO Chris J. Stern, DBA. "If we could include all the money spent from outside sources on Oxycyte research, the amount would be significantly greater. And we have indications that other researchers may be looking for funding for additional Oxycyte work that could speed up development of this promising product. This clearly underlines our intent to become a multi-product company with a strong portfolio of what could become a dozen or more indications in oxygen delivery to tissue."

About Synthetic Blood International Synthetic Blood International will soon be changing its name to Oxygen Biotherapeutics, Inc. pending completion of a reincorporation as approved by a vote of shareholders on June 17, 2008. A new stock trading symbol will be announced when it is assigned. The company is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit .

Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by Synthetic Blood International, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include descriptions of and references to potential applications of Oxycyte, the potential benefits of Oxycyte, forecasts of the company's prospects for a product portfolio, and possible additional outside sources of funding for Oxycyte research. Actual events or results may differ from Synthetic Blood International, Inc.'s expectations. There can be no assurance that any such research will be successful, that any additional outside funding for research will become available, that Oxycyte will be approved for market by the FDA, or that if approved will gain market acceptance. Additional information concerning these and other risk factors affecting Synthetic Blood International, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via . Synthetic Blood International, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE: Synthetic Blood International, Inc.
Abe Wischnia & AssociatesAbe Wischnia619-795-2345

Copyright Business Wire 2008

POS Pluristem gonna dilute again: PSTI NEWS

Pluristem Therapeutics Files $15M Common Stock Shelf >PSTI Last update: 6/18/2008 5:19:03 PM DOW JONES NEWSWIRES

Pluristem Therapeutics Inc. (PSTI) on Wednesday registered with the Securities and Exchange Commission to sell from time to time up to $15 million of common stock and warrants.

The Israel-based stem cell production technology company said it intends to use the net proceeds for research and product development activities, and for working capital and other general corporate purposes.

No underwriters were listed in the SEC filing.

Shares of the company closed Wednesday at $1.63 each, down 11 cents, or 6.32%. -Denise Jia, Dow Jones Newswires; 202-862-1359; denise.jia@dowjones.com (END) Dow Jones NewswiresJune 18, 2008 17:19 ET (21:19 GMT)

POS Pluristem gonna dilute again: PSTI NEWS

Pluristem Therapeutics Files $15M Common Stock Shelf >PSTI Last update: 6/18/2008 5:19:03 PM DOW JONES NEWSWIRES

Pluristem Therapeutics Inc. (PSTI) on Wednesday registered with the Securities and Exchange Commission to sell from time to time up to $15 million of common stock and warrants.

The Israel-based stem cell production technology company said it intends to use the net proceeds for research and product development activities, and for working capital and other general corporate purposes.

No underwriters were listed in the SEC filing.

Shares of the company closed Wednesday at $1.63 each, down 11 cents, or 6.32%. -Denise Jia, Dow Jones Newswires; 202-862-1359; denise.jia@dowjones.com (END) Dow Jones NewswiresJune 18, 2008 17:19 ET (21:19 GMT)

it's already moving...wait til the 9-5 crowd gets wind of this news...lol

lol...indeed!

Evergreen Solar Signs Two New Sales Contracts Totaling Approximately $600 MillionLast update: 6/18/2008 4:54:01 PM
Raises Contractual Backlog to More Than $1.7 Billion

MARLBORO, Mass., Jun 18, 2008 (BUSINESS WIRE) -- Evergreen Solar, Inc. (ESLR), a manufacturer of solar power panels with its proprietary, low-cost String Ribbon(TM) wafer technology, announced it has signed two new long-term sales contracts valued at approximately $600 million with United States-based groSolar and German-based Wagner & Co Solartechnik GmbH. These contracts extend through 2012 and bring the company's total contractual backlog to approximately $1.7 billion.

The solar panels for these two contracts and the two contracts previously announced in May will be manufactured at the company's Devens, Massachusetts facility, which will begin panel production in July. These four contracts represent approximately 65 percent of the expected 160MW of annual production capacity at Devens through 2013. Evergreen Solar also has six other customer contracts with a current total backlog of approximately $850 million, which will primarily be supplied by EverQ, its German-based joint venture.

"The four multi-year contracts that we have signed in the last 30 days continue to validate that our String Ribbon technology combined with the features and functionality of our solar panel design, provides a compelling value proposition for our customers," said Richard M. Feldt, Evergreen Solar's chairman, president and chief executive officer. "We continue in discussions with other potential customers as we look to commit up to 75% of Devens capacity to long term contracts."

About groSolar groSolar is a leading North American solar power company focused on designing, distributing and installing high quality solar electric and solar hot water systems. groSolar provides residential installation in the northeast and mid-Atlantic states, and commercial installation in California as well as the eastern US, serving other areas through an extensive dealer network. With a system of warehouses across the continent, groSolar has the broadest distribution capabilities of any solar provider. groSolar integrates components from leading solar manufacturers including Evergreen Solar into efficient solar energy systems for its customers that generate clean, reliable energy for decades. groSolar was also recently recognized as the second fastest growing company in Vermont and one of the best places to work in Vermont. For information, contact Kevin Ellis 1-800-498-5390 or Kelli Pippin at 1-800-374-4494 x3085.

About Wagner & Co Solartechnik GmbH As a leading PV system integrator in Germany, Wagner serves all the major markets in Europe through their extensive installer-network. Wagner also develops, manufactures and markets solar-hot water-systems for use throughout Europe. The Wagner-Academy helps to create high installation standards and profound knowledge for all market players they work with. Wagner also produces Europe's most efficient flat plate hot water collectors and the Company is well known for its "EURO-Collector" a premium, award-winning, high efficient product.For more information please visit .

About Evergreen Solar, Inc. Evergreen Solar, Inc. develops, manufactures and markets solar power products using proprietary, low-cost manufacturing technologies. The Company's patented wafer technology, known as String Ribbon, uses significantly less polysilicon than conventional processes. Evergreen's products provide reliable and environmentally clean electric power for residential and commercial applications globally.

For more information about the Company, please visit . Evergreen Solar(R) is a registered trademark and String Ribbon(TM) is a trademark of Evergreen Solar, Inc.

Safe Harbor Statement This press release contains forward-looking statements within the meaning of federal securities laws. Evergreen Solar cautions you that any statements contained in this press release that are not strictly historical statements constitute forward-looking statements. Such forward-looking statements include, but are not limited to, those related to: the start-up and future production capacity of the company's Devens manufacturing facility; the company's ability to protect the intellectual property incorporated in String Ribbon and other proprietary technologies; the company's ability to enter into additional long-term customer agreements; and the ultimate value of the customer contracts given changing market dynamics and governmental subsidy and incentive programs, currency fluctuations and related contractual pricing parameters. These statements are neither promises nor guarantees, and involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Such risks and uncertainties are identified in the company's filings with the Securities and Exchange Commission - including the company's Annual and Quarterly Reports on Forms 10-K and 10-Q filed with the SEC (copies of which may be obtained at the SEC's website at: ) - could impact the forward-looking statements contained in this press release. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Evergreen Solar disclaims any obligation to publicly update or revise any such statements to reflect any change in company expectations, or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. SOURCE: Evergreen Solar, Inc.
Evergreen Solar, Inc.Michael El-Hillow, 508-357-2221 x 7244Chief Financial Officerinvestors@evergreensolar.comCopyright Business Wire 2008

Good Life China (GLCC) Further Reduces Outstanding, The Float And The Short ListLast update: 6/18/2008 4:45:00 PM

TORONTO, June 18, 2008 /PRNewswire-FirstCall via COMTEX/ -- Good Life China Corp Pink Sheets: GLCC.PK is pleased to announce after the market has closed that it was successful in its task to further reduce its outstanding share structure, the float and the short sellers covering their position. The issuer intends to post the true certified copy of its outstanding share structure from the transfer agent Heritage Trust on pink sheets.com shortly. The issuer successfully reduced its float count from 71.5 million to about 43.3 million. This was achieved by recently announced warrants and options. The issuer has also identified its source of shorting, as offshore. The issuer's IR firm has been on the telephone contacting many broker-dealers advising them of how it wants its security managed. The issuer is using this opportunity to rescind its European only release sent out today. The issuer has no plans on securing any "secondary financing" and extends its gratitude to all the offers. The issuer today also passed a resolution to reduce its authorized shares to 200 million shares should it deem necessary, without further notice.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

SOURCE Good Life China Corporation
Copyright (C) 2008 PR Newswire. All rights reserved

AngioDynamics Completes Acquisition of U.S. and U.K. Diomed AssetsLast update: 6/18/2008 4:16:01 PM

QUEENSBURY, N.Y., Jun 18, 2008 (BUSINESS WIRE) -- AngioDynamics, Inc. (ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it has completed its acquisition of certain U.S. and U.K assets of Diomed, Inc. The purchase price for the assets is $11 million subject to adjustment for changes in working capital to be determined subsequent to the closing date.

"With the acquisition of Diomed's assets, AngioDynamics has substantially strengthened its position in the worldwide market for the treatment of varicose veins," said Eamonn Hobbs, President and CEO of AngioDynamics. "The Diomed endovenous laser products, combined with our existing venous product line, provide us with a compelling, comprehensive venous product offering for our customers and their patients. We will immediately begin integrating the Diomed business and expanding our sales organization. We welcome the Diomed customers and employees to the AngioDynamics family. This acquisition, combined with the recent settlement with VNUS Medical, provides AngioDynamics with valuable licenses to patents for use in endovenous laser therapy. This enhances our ability to provide physicians with innovative technologies for superior patient care in the high growth market to treat varicose veins," continued Mr. Hobbs.

Due to the higher than expected management time required to close the Diomed transactions and the VNUS settlement, the Company now plans to provide fiscal 2009 guidance during it's year end earnings conference call scheduled for July 24.

About AngioDynamics AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at .

Safe Harbor This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, without limitation, the ability of the Company to integrate the purchased Diomed businesses, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 2, 2007, may affect the actual results achieved by the Company. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

SOURCE: AngioDynamics, Inc.
AngioDynamics, Inc.D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608jgersuk@AngioDynamics.comorEVC Group, Inc.

Investor Relations:Doug Sherk or Donald Takaya, 415-896-6820dsherk@evcgroup.comdtakaya@evcgroup.com

Media:Chris Gale, 646-201-5431cgale@evcgroup.comCopyright Business Wire 2008


"So we sailed up to the sun...till we found a sea of green..."

AngioDynamics Completes Acquisition of U.S. and U.K. Diomed AssetsLast update: 6/18/2008 4:16:01 PM

QUEENSBURY, N.Y., Jun 18, 2008 (BUSINESS WIRE) -- AngioDynamics, Inc. (ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it has completed its acquisition of certain U.S. and U.K assets of Diomed, Inc. The purchase price for the assets is $11 million subject to adjustment for changes in working capital to be determined subsequent to the closing date.

"With the acquisition of Diomed's assets, AngioDynamics has substantially strengthened its position in the worldwide market for the treatment of varicose veins," said Eamonn Hobbs, President and CEO of AngioDynamics. "The Diomed endovenous laser products, combined with our existing venous product line, provide us with a compelling, comprehensive venous product offering for our customers and their patients. We will immediately begin integrating the Diomed business and expanding our sales organization. We welcome the Diomed customers and employees to the AngioDynamics family. This acquisition, combined with the recent settlement with VNUS Medical, provides AngioDynamics with valuable licenses to patents for use in endovenous laser therapy. This enhances our ability to provide physicians with innovative technologies for superior patient care in the high growth market to treat varicose veins," continued Mr. Hobbs.

Due to the higher than expected management time required to close the Diomed transactions and the VNUS settlement, the Company now plans to provide fiscal 2009 guidance during it's year end earnings conference call scheduled for July 24.

About AngioDynamics AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at .

Safe Harbor This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, without limitation, the ability of the Company to integrate the purchased Diomed businesses, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 2, 2007, may affect the actual results achieved by the Company. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

SOURCE: AngioDynamics, Inc.
AngioDynamics, Inc.D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608jgersuk@AngioDynamics.comorEVC Group, Inc.

Investor Relations:Doug Sherk or Donald Takaya, 415-896-6820dsherk@evcgroup.comdtakaya@evcgroup.com

Media:Chris Gale, 646-201-5431cgale@evcgroup.comCopyright Business Wire 2008



"So we sailed up to the sun...till we found a sea of green..."

ELN: prob w/biotech stocks w/mixed results news is initial pop on the pos news then sell on the neg part of news & bounces are typically small

yup & all the airlines went stiff lol

LCC AMR UAUA etc. all popped about the same time as crude reversed

http://www.alphatrade.com/E_Gate/tails/java/classes/resources/level2/marketMakerIDs/m.html

saw it on the daily list; dumped my freebies a while back (wasn't an easy task) for a fractional gain compared to my first batch...c'est la vie!

lotsa koolade guzzling on POS's going around these days it seems...lol ;o)

CIRT vs. CIRC was clear to ME all along...IMO today's pop was due to confusion with yesterday's CIRC PR, but that's just my opinion...& my last statement on this cuz I'm out.

GLTYA

EDIT: they should also clarify/emphasize their Intellectual Property position with respect to "cellubike" & "cardio-cor"...that would also be useful

I hope so for all who are still in...& hope you're also right about the restricted shares, but I've seen what appears to me to be dilution happening over the past couple of weeks, which is why I loaded more to average down (I hate doing that, BTW) & get out alive...the CIRT/CIRC confusion today was icing on the cake. :)

IMO, any & ALL future PRs should state that CIRT is not CirTran...seems to be causing too many problems...

GLTYA

they gotta clear up this CIRT vs. CIRC stuff, but wtf, eh? lol

agreed...& NO, I'm NOT an "insider" lol

there's probably still $$$ to be made on this one, Mr. Bailey may have in-licensed the name for all I know...

I didn't say it was a "scam"...the health/fitness industry is booming, but the "cellubkie" trademark is owned by a "company" in the Br. Virgin Islands & there's no info available on any patents/trademarks for "cardio-cor"...this was just a trade for me...no expectations of a gram slam home run...I'm not greedy when it comes to pinkies...99% of the time u end up a bagholder on them...

GLTY

they didn't work cuz the www.USPTO.gov server "times out" after a few moments of inactivity by a SPECIFIC USER.

there are simple instructions for conducting patent & trademark searches on www.uspto.gov check 'em out entering "cellubike" into the trademark search field & you will get TWO results.

click the serial number of each one & then on the "TARR Status" button above & you'll get this:

Thank you for your request. Here are the latest results from the TARR web server.

This page was generated by the TARR system on 2008-05-22 13:07:54 ET

Serial Number: 78881408 Assignment Information Trademark Document Retrieval

Registration Number: (NOT AVAILABLE)

Mark


(words only): CELLUBIKE

Standard Character claim: Yes

Current Status: Abandoned-Failure To Respond Or Late Response

Date of Status: 2007-05-22

Filing Date: 2006-05-11

Transformed into a National Application: No

Registration Date: (DATE NOT AVAILABLE)

Register: Supplemental

Law Office Assigned: LAW OFFICE 104


If you are the applicant or applicant's attorney and have questions about this file, please contact the Trademark Assistance Center at TrademarkAssistanceCenter@uspto.gov

Current Location: L4X -TMEG Law Office 104 - Examining Attorney Assigned

Date In Location: 2007-05-22




--------------------------------------------------------------------------------

LAST APPLICANT(S)/OWNER(S) OF RECORD

--------------------------------------------------------------------------------
1. Bailey, Wayne K., Reinhardt, Ellen

Address:
Bailey, Wayne K., Reinhardt, Ellen
1848-M West 11th St.
Upland, CA 91786
United States
Legal Entity Type: Corporation
State or Country of Incorporation: Nevada
Phone Number: 800-946-9391
Fax Number: 909-946-9394

2. Bailey, Wayne K., Reinhardt, Ellen

Address:
Bailey, Wayne K., Reinhardt, Ellen
1848-M West 11th St.
Upland, CA 91786
United States
Legal Entity Type: Corporation
State or Country of Incorporation: Nevada
Phone Number: 800-946-9391
Fax Number: 909-946-9394


--------------------------------------------------------------------------------

GOODS AND/OR SERVICES

--------------------------------------------------------------------------------
International Class: 012
Class Status: Active
bicycle NG012AT
Basis: 1(a)
First Use Date: 2005-06-01
First Use in Commerce Date: 2005-06-01


--------------------------------------------------------------------------------

ADDITIONAL INFORMATION

--------------------------------------------------------------------------------
Description of Mark: The mark consists of Red and Black with a curved line underneath.


--------------------------------------------------------------------------------

MADRID PROTOCOL INFORMATION

--------------------------------------------------------------------------------
(NOT AVAILABLE)


--------------------------------------------------------------------------------

PROSECUTION HISTORY
--------------------------------------------------------------------------------
NOTE: To view any document referenced below, click on the link to "Trademark Document Retrieval" shown near the top of this page.


2007-05-23 - Abandonment Notice Mailed - Failure To Respond

2007-05-22 - Abandonment - Failure To Respond Or Late Response

2006-10-22 - Non-final action e-mailed

2006-10-22 - Non-Final Action Written

2006-10-13 - Assigned To Examiner

2006-05-17 - New Application Entered In Tram


--------------------------------------------------------------------------------

ATTORNEY/CORRESPONDENT INFORMATION

--------------------------------------------------------------------------------
Correspondent
BAILEY, WAYNE K, REINHARDT, ELLEN
1848 W 11TH ST STE M
UPLAND, CA 91786-8400
Phone Number: 800-946-9391
Fax Number: 909-946-9394


and this:

Thank you for your request. Here are the latest results from the TARR web server.

This page was generated by the TARR system on 2008-05-22 13:08:44 ET

Serial Number: 78569038 Assignment Information Trademark Document Retrieval

Registration Number: 3341034

Mark


(words only): CELLUBIKE

Standard Character claim: Yes

Current Status: Registered.

Date of Status: 2007-11-20

Filing Date: 2005-02-16

Transformed into a National Application: No

Registration Date: 2007-11-20

Register: Principal

Law Office Assigned: LAW OFFICE 116


If you are the applicant or applicant's attorney and have questions about this file, please contact the Trademark Assistance Center at TrademarkAssistanceCenter@uspto.gov

Current Location: 650 -Publication And Issue Section

Date In Location: 2007-10-16




--------------------------------------------------------------------------------

LAST APPLICANT(S)/OWNER(S) OF RECORD

--------------------------------------------------------------------------------
1. Intant Tan International, Ltd.

Address:
Intant Tan International, Ltd.
P.O. Box 3159
Roadtown, Tortola
Br. Virgin Islands
Legal Entity Type: Corporation
State or Country of Incorporation: Br. Virgin Islands
Phone Number: (801) 533-0320
Fax Number: (801) 533-0323


--------------------------------------------------------------------------------

GOODS AND/OR SERVICES

--------------------------------------------------------------------------------
International Class: 028
Class Status: Active
Exercise Equipment, namely stationary bicycles
Basis: 1(a)
First Use Date: 2004-09-01
First Use in Commerce Date: 2004-10-26


--------------------------------------------------------------------------------

ADDITIONAL INFORMATION

--------------------------------------------------------------------------------
(NOT AVAILABLE)


--------------------------------------------------------------------------------

MADRID PROTOCOL INFORMATION

--------------------------------------------------------------------------------
(NOT AVAILABLE)


--------------------------------------------------------------------------------

PROSECUTION HISTORY
--------------------------------------------------------------------------------
NOTE: To view any document referenced below, click on the link to "Trademark Document Retrieval" shown near the top of this page.


2007-12-04 - Undeliverable Mail - Corresp. Remailed

2007-11-20 - Registered - Principal Register

2007-10-16 - Law Office Registration Review Completed

2007-10-16 - Assigned To LIE

2007-09-17 - Allowed for Registration - Principal Register (SOU accepted)

2007-08-25 - Statement of use processing complete

2007-07-20 - Amendment to Use filed

2007-07-20 - TEAS Statement of Use Received

2007-02-20 - Notice of allowance - mailed

2006-12-19 - Extension Of Time To Oppose Process - Terminated

2006-06-22 - Withdrawal Of Attorney Granted

2006-06-22 - TEAS Withdrawal Of Attorney Received

2006-06-21 - Extension Of Time To Oppose Received

2006-06-06 - Published for opposition

2006-05-17 - Notice of publication

2006-04-20 - Law Office Publication Review Completed

2006-04-14 - Assigned To LIE

2006-04-08 - Approved for Pub - Principal Register (Initial exam)

2006-03-13 - Teas/Email Correspondence Entered

2006-03-09 - Communication received from applicant

2006-03-09 - TEAS Response to Office Action Received

2005-09-15 - Non-final action e-mailed

2005-09-15 - Non-Final Action Written

2005-09-13 - Assigned To Examiner

2005-07-19 - TEAS Change Of Correspondence Received

2005-02-28 - New Application Entered In Tram


--------------------------------------------------------------------------------

ATTORNEY/CORRESPONDENT INFORMATION

--------------------------------------------------------------------------------
Correspondent
Instant Tan International, Ltd.
656 East 11400 South, Suite H
Draper Utah 84020 United States

Domestic Representative
Randall B. Bateman
Phone Number: (801) 533-0320
Fax Number: (801) 533-0323


figure it out & good luck!

nope...I'm a seller who's moving on in the pinkie alphabet soup...check your DD for yourselves.

GLTY